Omalizumab (Drug Plan Submission)


( Last Updated : October 6, 2015)
Generic Name:
Omalizumab (Drug Plan Submission)
Project Status:
Complete
Therapeutic Area:
Asthma, severe persistent
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Call for patient/clinician input open:
Brand Name:
Xolair
Project Line:
Reimbursement Review
Project Number:
SR0457-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC

Details


Submission Type:
Drug Plan Initiated
Indications:
Asthma, severe persistent
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation: